GlassScriptPhysician profile
Amy K Rivas
NPI 1356780464
$3,158.55
in general payments reported to CMS, 2019-2025
22 companies · $2,073 in 2025
The $2,073 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.96 · 2022: $77.19 · 2023: $140 · 2024: $840 · 2025: $2,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923 · Travel and Lodging: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,923.01 |
| Travel and Lodging | $129.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $969.74 | 2024-2025 | Minimed 780g, Corevalve Evolut R |
| Dexcom, INC. | $877.82 | 2024-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $342.07 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $223.85 | 2023-2025 | Imfinzi, Calquence |
| Edwards Lifesciences Corporation | $127.23 | 2022-2025 | |
| Daiichi Sankyo INC. | $101.07 | 2024-2025 | Datroway, Injectafer, Enhertu |
| Jazz Pharmaceuticals INC. | $96.21 | 2024-2025 | |
| Pfizer INC. | $88.06 | 2024-2025 | |
| Incyte Corporation | $41.74 | 2025 | Jakafi, Monjuvi, Pemazyre |
| Recordati_rare_diseases_inc. | $41.31 | 2024 | Signifor Lar, Isturisa |
| Abbott Laboratories | $28.96 | 2021 | |
| Adaptive Biotechnologies Corporation | $27.92 | 2024 | Clonoseq |
| Merck Sharp & Dohme LLC | $22.25 | 2025 | Lynparza, Keytruda |
| Janssen Biotech, INC. | $22.24 | 2024 | Erleada |
| Genmab U.S., INC. | $21.89 | 2024 | Epkinly |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $20.67 | 2022 | |
| Beta Bionics, INC. | $20.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Lilly USA, LLC | $20.00 | 2024 | Jardiance |
| Genentech USA, INC. | $18.42 | 2024 | Columvi, Lunsumio, Polivy |
| E.R. Squibb & Sons, L.L.C. | $18.09 | 2024 | Opdivo |
| Janssen Pharmaceuticals, INC | $14.66 | 2022 | |
| Abbvie INC. | $13.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Rivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.